Certara (NASDAQ:CERT) Given New $15.00 Price Target at KeyCorp

Certara (NASDAQ:CERT) had its price objective decreased by KeyCorp from $18.00 to $15.00 in a report released on Monday,Benzinga reports. KeyCorp currently has an overweight rating on the stock.

Several other analysts have also commented on CERT. Morgan Stanley initiated coverage on Certara in a research note on Thursday, July 3rd. They issued an “equal weight” rating and a $16.00 price target on the stock. Barclays raised Certara from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $11.00 to $14.00 in a research note on Thursday, May 8th. JMP Securities reissued a “market perform” rating on shares of Certara in a research note on Tuesday, May 6th. Finally, Robert W. Baird boosted their price objective on Certara from $9.00 to $13.00 and gave the stock a “neutral” rating in a research note on Friday, April 11th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $15.29.

Certara Stock Performance

Shares of NASDAQ CERT opened at $11.14 on Monday. The company has a quick ratio of 2.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.27. The business’s 50 day moving average is $11.39 and its two-hundred day moving average is $11.88. The company has a market cap of $1.81 billion, a P/E ratio of -557.00 and a beta of 1.43. Certara has a 12 month low of $8.64 and a 12 month high of $16.93.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.04. Certara had a positive return on equity of 5.05% and a negative net margin of 0.67%. The company had revenue of $106.00 million for the quarter, compared to analyst estimates of $104.44 million. During the same quarter last year, the firm earned $0.10 EPS. Certara’s revenue for the quarter was up 9.7% compared to the same quarter last year. On average, equities analysts expect that Certara will post 0.28 EPS for the current year.

Institutional Investors Weigh In On Certara

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Certara by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 12,437,089 shares of the company’s stock worth $132,455,000 after acquiring an additional 38,068 shares during the last quarter. ArrowMark Colorado Holdings LLC increased its holdings in Certara by 164.2% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company’s stock valued at $66,171,000 after purchasing an additional 3,861,674 shares during the last quarter. Geneva Capital Management LLC increased its holdings in Certara by 3.9% in the first quarter. Geneva Capital Management LLC now owns 5,671,689 shares of the company’s stock valued at $56,150,000 after purchasing an additional 213,089 shares during the last quarter. Teacher Retirement System of Texas increased its holdings in Certara by 13.9% in the fourth quarter. Teacher Retirement System of Texas now owns 4,557,951 shares of the company’s stock valued at $48,542,000 after purchasing an additional 557,348 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in Certara by 13.6% in the first quarter. Ameriprise Financial Inc. now owns 4,295,566 shares of the company’s stock valued at $42,526,000 after purchasing an additional 515,911 shares during the last quarter. Institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.